+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview - US, South #2

  • ID: 4775339
  • Report
  • February 2019
  • Region: United States
  • 11 pages
  • Datamonitor Healthcare
1 of 1

Enquire about COVID-19 updates for this product.

Enquire Now
Overview
This interview provides a thorough description of hepatocellular carcinoma (HCC) treatment in the US.

All targeted therapies available for HCC treatment are discussed, as well as a discussion of Phase III pipeline drugs and the potential impact these therapies would have if they gain approval.
Note: Product cover images may vary from those shown
2 of 1

Loading
LOADING...

Adroll
adroll